Exelixis Stock

Exelixis Equity

The The Equity of Exelixis (EXEL) as of Aug 22, 2026 is 2.16 B USD. In the previous year, The Equity was 2.24 B USD — a change of -3.69% (lower).

Equity

2.16 BUSD

YoY

-3.69%

Last updated:

In 2026, Exelixis's equity was 2.16 B USD, a -3.69% increase from the 2.24 B USD equity in the previous year.

The Exelixis Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
1.29 B USD
Jan 1, 2019
1.69 B USD
Jan 1, 2020
1.88 B USD
Jan 1, 2021
2.21 B USD
Jan 1, 2022
2.49 B USD
Jan 1, 2023
2.26 B USD
Jan 1, 2024
2.24 B USD
Jan 1, 2025
2.16 B USD
The Exelixis Equity history
YEAREquityYoY
2.16 BUSD-3.69%
2.24 BUSD-0.87%
2.26 BUSD-9.02%
2.49 BUSD+12.57%
2.21 BUSD+17.64%
1.88 BUSD+11.46%
1.69 BUSD+30.95%
1.29 BUSD+351.80%
284.96 MUSD+219.04%
89.32 MUSD-185.63%
-104.30 MUSD-9.17%
-114.83 MUSD
Access this data via the Eulerpool API

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Exelixis's Equity

Exelixis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Exelixis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Exelixis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Exelixis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Exelixis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Exelixis stock

The Equity of Exelixis is 2.16 B USD in 2026.

The Equity of Exelixis changed from 2.24 B USD to 2.16 B USD, representing a -3.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Exelixis since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Exelixis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Exelixis

All Key Metrics — Exelixis